American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
May 13, 2021
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Andrew, and I appreciate all of you being here with us today. Prior to handing things off to management, I'd like to share a few comments regarding forward-looking statements. Kindly be aware that any number of things we might say during this conference call regarding the company's future expectations, plans and prospects are considered forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Results in reality could differ significantly from what those forward-looking statements suggest, owing to a range of important factors, among them those covered in the company's SEC filings; that includes the annual report on Form 10-K covering the year that ended December 31, 2020, along with the definitive proxy statement for the Annual Meeting of Shareholders scheduled for June 25, 2021. No obligation is taken on by the company to refresh any information in this conference call. At this point I'd like to pass the call to Ray Stachowiak, CEO of AMS. Ray?
Ray Stachowiak
executiveThanks, Stephanie, and hello to all of you this afternoon. We appreciate your presence on today's call covering our results for the first quarter of 2021. I'll make a few opening comments, after which Craig Tagawa — our President, COO and CFO — will walk through business and operational performance. Alexis Wallace, who serves as our Chief Accounting Officer, will follow with a financial review. After that, Craig, Alexis, Ernie Bates — our Senior VP, Sales and Business Development and International Assets — and I will take your questions. Only 5 weeks have passed since our year-end call, and during that time we announced a significant step that has strengthened our balance sheet and should boost long-term shareholder value. That step, made public on April 13, was entering a banking relationship with Fifth Third Bank N.A., the main subsidiary of Fifth Third Bancorp — a diversified bank holding company based in Cincinnati, Ohio, with assets exceeding $200 billion. The $22 million credit agreement we signed with Fifth Third marks a milestone for our company. It is made up of 3 facilities: first, a term loan of $9.5 million that refinanced $6.8 million of domestic Gamma Knife debt; another $1.6 million went toward 2 Gamma Knife free loads with 2 customers that had recently extended their agreements; the last $1.1 million remains available for future projects. Facility number two is a $5.5 million term loan that refinanced the company's PBRT equipment debt and additionally provided working capital. That debt had been scheduled to mature in the fourth quarter of 2021. The credit agreement's third facility is a $7 million revolving line of credit, intended to give us more flexibility when negotiating future projects and to serve general corporate purposes. These term loans will bring substantial reductions in principal payments, which we estimate at $5.9 million across the next 12 months. Interest expense savings will exceed $350,000 during that same period. We will also unlock $300,000 in cash that previously had been restricted. Taken as a whole, the transaction instantly reduces our cost of capital and produced a swing to a positive working capital position of $4.2 million at the close of the first quarter, versus a negative $1.5 million on December 31, 2020. Our new relationship with Fifth Third forms a key part of our strategy for increasing growth. Possibly most significant: with the $5 million in cash on our balance sheet as of March 31, 2021, the positive cash flow we anticipate for the rest of the year, and now supplemented by the $7 million line of credit, we hold greater resources and stand in a much firmer position to negotiate with potential customers on new projects. Together with our expanded product and financial offerings and the recent asset write-downs, I believe these decisive actions set us on the right path toward our goal of increased growth and sustained profitability. Even in Q1, before those measures could fully take effect, our results came in at breakeven on soft volumes. If the pandemic keeps easing, we anticipate patient volumes will return to normal. At this point I'll hand things over to Craig, who will walk through the operational review for the first quarter. Craig?
Craig Tagawa
executiveThanks, Ray, and good afternoon to all of you. For the first quarter, we posted results at breakeven on total revenue of roughly $4.4 million, which represents a 4.5% decrease from the revenue we saw in the first quarter of last year — that was the only quarter of 2020 that was mostly untouched by the pandemic. Our Gamma Knife revenue in Q1 came back from the pandemic's lowest points and matched a solid quarter a year ago. Both of our Gamma Knife centers located in Peru and Ecuador delivered a robust first quarter. That said, COVID-19 continues to weigh on PBRT volumes. And when you add in planned maintenance, fractions declined once again during the first quarter. Revenue in the first quarter for the proton therapy system the company installed at Orlando Health fell 8.7% relative to the first quarter of 2020. On a period-over-period basis, a higher average reimbursement per fraction helped partially offset the reduced fraction count. Gamma Knife revenue came in at $2.9 million, matching the first quarter of 2020, since a drop in volume was offset by a rise in the average reimbursement rate. Total proton therapy fractions fell 26.6%, driven mainly by the ongoing effects of COVID-19, made worse by downtime tied to maintenance. Gamma Knife procedures dropped 5.6%, coming in at 355 for the first quarter versus 376 during the same period a year earlier. That decline largely stemmed from a contract that expired in the fourth quarter of 2020 along with another contract in the first quarter of 2021, partly offset by our acquisition of GKCE in the second quarter of 2020. Gamma Knife volumes at centers in operation matched Gamma Knife volumes at those very same centers in the comparable period of the prior year. Gross margin for the current first quarter rose to 32.9% of revenue, up from a gross margin of 30.5% of revenue in the first quarter a year ago. Depreciation and amortization declined by $449,000, or 27.3%, in the current quarter. This was mostly attributable to a contract that expired in the fourth quarter of 2020 and another contract in the first quarter of 2021. On top of that, writing off some impaired Gamma Knife equipment at year-end removed depreciation expense for that equipment in the current period relative to last year. Selling and administrative costs fell 10.5% period-over-period, mainly because of lower legal and other fees. We anticipate further reductions in administrative expenses this year as we concentrate on optimizing our cost structure. Net income was $29,000, compared with a net loss of $135,000 in the first quarter of last year. That $164,000 positive swing resulted from the decrease in depreciation expense along with selling and administrative costs. We kept building our cash balances during the first quarter and had just over $5 million as of March 31. In the first quarter of 2021, we finished 2 Cobalt-60 reloads. We have a number of other upgrades pending in our pipeline, among them a Gamma Knife center in Ecuador, which is set for installation this fall and which will rank among the few Gamma Knifes anywhere in South America. Additionally, we expect to carry out a Cobalt-60 reload during Q4, something we're basing on an extension to a contract that was signed not long ago. Talks continue with other possible customers regarding the broader range of products we now offer, which Ray mentioned earlier. Having said that, I'd like to hand things over now to Alexis so she can walk through the financials in detail. Alexis?
Alexis Wallace
executiveThank you, Craig, and good afternoon to all of you. Before I get into my prepared comments, I want to direct everyone to the first quarter earnings press release we put out earlier today. If anyone still needs a copy, you can find it on our website, ashs.com, listed under Press Releases within the Investors tab. Now, moving on to what we saw in the first quarter. For the 3 months that ended March 31, 2021, total revenue came in at $4,364,000, which represents a decline of 4.5% versus the $4,568,000 we reported for the first quarter of 2020. Revenue during the first quarter from the company's proton therapy system installed at Orlando Health in Florida reached $1,531,000, down 8.7% from the first quarter of 2020. Total proton therapy fractions fell 26.6%, landing at 1,231 for the 3-month period ended March 31, 2021, versus 1,676 during that same period a year earlier. Revenue from the company's Gamma Knife operations was $2,892,000, which was flat compared with the first quarter of 2020. Gamma Knife procedures declined by 5.6%, coming to 355 in the first quarter of 2021, down from 376 during the same period the prior year. Gamma Knife volumes at centers in operation were flat relative to Gamma Knife volumes at those very same centers during the equivalent period last year. Gross margin for the first quarter of 2021 rose to $1,434,000, or 32.9% of revenue, versus a gross margin of $1,394,000, or 30.5% of revenue, in the first quarter of 2020. Selling and administrative costs came down to $1,084,000 in the first quarter, a 10.5% reduction from $1,211,000 in the first quarter of 2020. Operating income for the first quarter of 2021 was $90,000, compared with an operating loss of $99,000 in the first quarter of 2020. Net income for the first quarter of 2021 was $29,000, or $0.00 per diluted share; that compares with a net loss of $135,000, or $0.02 per diluted share, in the first quarter of 2020. Weighted average diluted common shares stood at 6,322,000 and 6,153,000 for the first quarter of 2021 and 2020, respectively. Adjusted EBITDA, which is a non-GAAP financial measure, was $1,600,000 for the first quarter of 2021, versus $1,822,000 for the first quarter of 2020. As of March 31, 2021, cash, cash equivalents and restricted cash totaled $5,013,000, compared with $4,325,000 at December 31, 2020. Shareholders' equity at March 31, 2021, was $23,844,000, or $4.11 per outstanding share; that compares with shareholders' equity of $23,650,000, or $4.08 per outstanding share, at December 31, 2020; that wraps up the formal portion of our presentation. Andrew, at this point we'd like to hand the call back to you for questions.
Executive
executiveJeffrey Cohen here. I'm interested in that revolver facility of yours, and I wanted to know if you've actually pulled any funds from it yet.
Ray Stachowiak
executiveJeff, I appreciate the question. Ray Stachowiak here. No, we haven't taken anything from our revolver. We simply haven't had a reason to.
Leonard Dunn
analystSo actually, I've got two things I want to ask, since clearly expanding revenue is the number one priority. Besides that single Gamma Knife you mentioned, do you have additional ones in the works? And part of what I'm asking is, I'm aware that some were written off. If a customer can set up the appropriate contract with you, could some of those still potentially be placed even after being written off?
Ray Stachowiak
executiveLenny, it's Ray here. I appreciate you calling in, and it's good to have you back on our quarterly call. We keep looking for sites where we can put our Gamma Knifes, whether those are pre-owned units coming from former accounts or brand-new Gamma Knife placements. There's nothing we can share at this point. That said, we keep hunting and keep pushing these opportunities forward. Like we've said before, the sales cycle here is extremely lengthy, and these deals simply require patience. I think I can probably tell you, though, that right now we have a greater number of conversations underway than we've had lately.
Leonard Dunn
analystWith the COVID situation easing somewhat, I'd imagine that's the case. Plus, when it comes to the proton beam, Mevion has installed a number of them, and hospitals are purchasing them directly. Still, my sense is that a pay-per-use segment continues to exist, and there's a chance of completing 1 or 2 more of these. Is anything currently in the pipeline? I'm not looking for details.
Ray Stachowiak
executiveOur efforts carry on toward locating good sites for proton beam therapy, mainly within the U.S.
Leonard Dunn
analystYes. All right. So my second question concerns the opposite portion of the balance sheet, where that costly office rent remains. Has any attempt been made to perhaps sublet it and relocate to a location that would be more logical?
Ray Stachowiak
executiveLet me reassure you that indeed, we have examined it and are doing everything we can to pursue that possibility. The market for office space, as you're aware, is quite weak given — under the current conditions.
Leonard Dunn
analystSo when is your lease up?
Ray Stachowiak
executiveThat's something I don't remember. Craig, any idea on that?
Craig Tagawa
executiveI think it's — there's another 3 years to go approximately.
Leonard Dunn
analystWith any luck, some new company will be looking for premium square footage, which would let you sign a new lease.
Ray Stachowiak
executiveWe appreciate you being with us. American Shared has a future that has us genuinely thrilled. Should anything come up that you'd like to ask about ahead of our upcoming call covering the second quarter, scheduled for the middle of August, don't hesitate to reach out to us straight away. Our wish for everyone is that you remain well and enjoy a wonderful day. Farewell.
Operator
operatorThat brings today's presentation to a close. We appreciate everyone joining us. You're welcome to leave the call now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.